Akorn Stock Price, News & Analysis (NASDAQ:AKRX)

$33.01 -0.05 (-0.15 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$33.01
Today's Range$32.72 - $33.18
52-Week Range$17.74 - $34.00
Volume1.87 million shs
Average Volume1.40 million shs
Market Capitalization$4.13 billion
P/E Ratio33.34
Dividend YieldN/A
Beta1.33

About Akorn (NASDAQ:AKRX)

Akorn logoAkorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals in a range of dosage forms, including sterile ophthalmics, injectables and inhalants and non-sterile oral liquids, topicals and nasal sprays and otics. The Consumer Health segment consists of branded and private-label OTC products and animal health products dispensed by veterinary professionals. Its branded and private-label OTC products are focused on ophthalmics, including a dry eye treatment TheraTears Therapy for Your Eyes.

Receive AKRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:AKRX
CUSIP00972810
Phone847-279-6100

Debt

Debt-to-Equity Ratio0.92%
Current Ratio4.16%
Quick Ratio3.17%

Price-To-Earnings

Trailing P/E Ratio33.3434343434343
Forward P/E Ratio34.75
P/E Growth1.7

Sales & Book Value

Annual Sales$1.12 billion
Price / Sales3.70
Cash Flow$2.97 per share
Price / Cash11.12
Book Value$6.54 per share
Price / Book5.05

Profitability

Trailing EPS$0.99
Net Income$184.24 million
Net Margins7.79%
Return on Equity15.14%
Return on Assets6.51%

Miscellaneous

Employees2,388
Outstanding Shares125,070,000

Akorn (NASDAQ:AKRX) Frequently Asked Questions

What is Akorn's stock symbol?

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

How were Akorn's earnings last quarter?

Akorn, Inc. (NASDAQ:AKRX) announced its quarterly earnings results on Thursday, August, 4th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.03. The business earned $280.70 million during the quarter, compared to the consensus estimate of $272.99 million. Akorn had a return on equity of 15.14% and a net margin of 7.79%. The company's quarterly revenue was up 27.1% compared to the same quarter last year. View Akorn's Earnings History.

Where is Akorn's stock going? Where will Akorn's stock price be in 2018?

8 Wall Street analysts have issued 12-month price targets for Akorn's stock. Their predictions range from $24.00 to $34.00. On average, they expect Akorn's stock price to reach $30.20 in the next twelve months. View Analyst Ratings for Akorn.

What are Wall Street analysts saying about Akorn stock?

Here are some recent quotes from research analysts about Akorn stock:

  • 1. According to Zacks Investment Research, "Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. They also market ophthalmic surgical instruments and related products. Customers include physicians, optometrists, wholesalers, group purchasing organizations and other pharmaceutical companies. They also provide contract manufacturing services. " (10/24/2017)
  • 2. Royal Bank of Canada analysts commented, "We now see two major hurdles lifted (i) a much needed reset on 2017 EPS and (ii) greater comfort on new approvals from Decatur. From here, debate will move to whether there is enough new launch revenue to offset erosion and drive growth beyond 2017. Story is de-risked meaningfully but we are still struggling to find growth off lower base. Target down to $21... Leading into 4Q we have been concerned that Street numbers for 2017 were meaningfully too high and that new approvals were not coming from the Decatur facility. First time 2017 guidance of $1.53 to $1.72 should re-set the Street's $2.17, lowering the bar for this year, and last night's announced approvals out of Decatur assuaged concerns around facility risk. In other words, two major concerns around this stock have now been removed. We have updated our model and our 2017-19E EPS move roughly $0.30 lower but still show little growth at $1.61, $1.64 and $1.69 (but we think guidance is reasonable). The re-set reduced risk but pushes valuation to 9.3x our 2018E EBITDA which is not necessarily inexpensive against the limited growth in our model." (3/2/2017)

Are investors shorting Akorn?

Akorn saw a increase in short interest in the month of December. As of December 29th, there was short interest totalling 25,205,843 shares, an increase of 5.3% from the December 15th total of 26,629,723 shares. Based on an average daily volume of 1,446,126 shares, the days-to-cover ratio is presently 17.4 days. Approximately 27.1% of the company's stock are sold short.

Who are some of Akorn's key competitors?

Who are Akorn's key executives?

Akorn's management team includes the folowing people:

  • Alan D. Weinstein, Chairman of the Board (Age 74)
  • Rajat Rai, Chief Executive Officer (Age 50)
  • Duane A. Portwood, Chief Financial Officer, Executive Vice President (Age 50)
  • Bruce K Kutinsky, Chief Operating Officer (Age 51)
  • Joseph P. Bonaccorsi, Executive Vice President, General Counsel, Secretary (Age 51)
  • Jonathon Kafer, Executive Vice President - Sales and Marketing (Age 53)
  • Steven Joseph Lichter, Executive Vice President - Pharmaceutical Operations (Age 58)
  • Randall E. Pollard, Senior Vice President, Chief Accounting Officer, Corporate Controller (Age 45)
  • Brian Tambi, Director (Age 71)
  • Kenneth S. Abramowitz, Independent Director (Age 66)

Who owns Akorn stock?

Akorn's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.32%), Bank of Montreal Can (0.13%) and State of Alaska Department of Revenue (0.00%). Company insiders that own Akorn stock include Alan D Weinstein, Brian Tambi, Bruce Kutinsky, Joseph Bonaccorsi, Kenneth Abramowitz and Ronald M Johnson. View Institutional Ownership Trends for Akorn.

Who bought Akorn stock? Who is buying Akorn stock?

Akorn's stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Schwab Charles Investment Management Inc. and State of Alaska Department of Revenue. View Insider Buying and Selling for Akorn.

How do I buy Akorn stock?

Shares of Akorn can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akorn's stock price today?

One share of Akorn stock can currently be purchased for approximately $33.01.

How big of a company is Akorn?

Akorn has a market capitalization of $4.13 billion and generates $1.12 billion in revenue each year. The company earns $184.24 million in net income (profit) each year or $0.99 on an earnings per share basis. Akorn employs 2,388 workers across the globe.

How can I contact Akorn?

Akorn's mailing address is 1925 W. FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]


MarketBeat Community Rating for Akorn (AKRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  380 (Vote Outperform)
Underperform Votes:  302 (Vote Underperform)
Total Votes:  682
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Akorn (NASDAQ:AKRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.111.912.00
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
8 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
10 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.20$31.83$29.13$31.20
Price Target Upside: 7.13% downside2.11% downside12.48% downside7.42% downside

Akorn (NASDAQ:AKRX) Consensus Price Target History

Price Target History for Akorn (NASDAQ:AKRX)

Akorn (NASDAQ:AKRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/29/2017Jefferies GroupSet Price TargetHold$34.00N/AView Rating Details
10/22/2017Piper Jaffray CompaniesSet Price TargetHold$34.00N/AView Rating Details
10/3/2017Royal Bank of CanadaReiterated RatingHold$34.00HighView Rating Details
4/25/2017GabelliReiterated RatingBuy -> HoldHighView Rating Details
4/25/2017William BlairDowngradeOutperform -> Market PerformHighView Rating Details
4/25/2017Craig HallumDowngradeBuy -> HoldHighView Rating Details
4/10/2017Deutsche BankReiterated RatingHold$24.00LowView Rating Details
3/10/2017WallachBeth CapitalBoost Price TargetHold -> Hold$22.00 -> $25.00LowView Rating Details
12/29/2016GuggenheimReiterated RatingBuy$40.00N/AView Rating Details
12/1/2016Goldman Sachs GroupInitiated CoverageSell$20.00N/AView Rating Details
11/7/2016Bank of AmericaDowngradeBuy -> Underperform$22.00N/AView Rating Details
8/5/2016JPMorgan Chase & Co.Set Price TargetBuy$45.00N/AView Rating Details
8/2/2016Raymond James FinancialDowngradeOutperform -> Market PerformN/AView Rating Details
8/2/2016CitigroupDowngradeMarket Perform$33.80 -> $34.00N/AView Rating Details
5/26/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
3/23/2016Susquehanna BancsharesLower Price TargetNeutral$32.00 -> $30.00N/AView Rating Details
3/22/2016S&P Equity ResearchLower Price Target$25.98 -> $21.97N/AView Rating Details
3/21/2016NomuraLower Price TargetBuy$46.00 -> $42.00N/AView Rating Details
(Data available from 1/20/2016 forward)

Earnings

Akorn (NASDAQ:AKRX) Earnings History and Estimates Chart

Earnings by Quarter for Akorn (NASDAQ:AKRX)

Akorn (NASDAQ AKRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2017Q2 2017$0.12ViewN/AView Earnings Details
5/4/2017Q1 2017$0.40ViewN/AView Earnings Details
3/1/2017Q4 2016$0.57$0.58$287.91 million$283.70 millionViewListenView Earnings Details
11/3/2016Q316$0.54$0.56$267.04 million$284.00 millionViewListenView Earnings Details
8/4/2016Q216$0.55$0.58$272.99 million$280.70 millionViewListenView Earnings Details
5/16/2016Q116$0.43$0.54$264.88 million$268.35 millionViewListenView Earnings Details
2/26/2015Q414$0.46$0.49$218.87 million$227.80 millionViewListenView Earnings Details
11/6/2014Q314$0.25$0.27$155.20 million$132.70 millionViewListenView Earnings Details
8/5/2014Q214$0.18$0.23$145.16 million$150.70 millionViewListenView Earnings Details
5/6/2014Q114$0.15$0.16$91.44 million$90.60 millionViewN/AView Earnings Details
3/3/2014Q413$0.14$0.14$83.37 million$85.00 millionViewN/AView Earnings Details
11/5/2013Q3 2013$0.13$0.14ViewN/AView Earnings Details
8/6/2013Q2 2013$0.13$0.14$75.06 million$77.00 millionViewN/AView Earnings Details
5/7/2013Q1 2013$0.14$0.13$74.07 million$73.90 millionViewN/AView Earnings Details
2/26/2013Q4 2012$0.12$0.13$69.42 million$71.50 millionViewN/AView Earnings Details
11/6/2012Q312$0.13$0.12$69.59 million$69.60 millionViewN/AView Earnings Details
8/7/2012$0.12$0.12ViewN/AView Earnings Details
5/8/2012$0.12$0.13ViewN/AView Earnings Details
3/6/2012$0.09$0.11ViewN/AView Earnings Details
11/1/2011$0.06$0.13ViewN/AView Earnings Details
8/2/2011Q2 2011$0.04$0.04ViewN/AView Earnings Details
5/3/2011Q1 2011$0.03$0.06ViewN/AView Earnings Details
3/1/2011Q4 2010$0.03$0.04ViewN/AView Earnings Details
11/1/2010Q3 2010$0.04ViewN/AView Earnings Details
8/3/2010Q2 2010($0.01)($0.10)ViewN/AView Earnings Details
5/3/2010Q1 2010$0.02ViewN/AView Earnings Details
3/15/2010Q4 2009($0.02)($0.01)ViewN/AView Earnings Details
11/10/2009Q3 2009($0.08)($0.04)ViewN/AView Earnings Details
8/11/2009Q2 2009($0.07)ViewN/AView Earnings Details
5/12/2009Q1 2009($0.03)ViewN/AView Earnings Details
11/3/2008Q3 2008$0.03ViewN/AView Earnings Details
7/31/2008Q2 2008($0.03)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.06)ViewN/AView Earnings Details
3/11/2008Q4 2007($0.06)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Akorn (NASDAQ:AKRX) Earnings Estimates

Current Year EPS Consensus Estimate: $0.95 EPS
Next Year EPS Consensus Estimate: $1.16 EPS

Dividends

Dividend History for Akorn (NASDAQ:AKRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Akorn (NASDAQ AKRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.20%
Institutional Ownership Percentage: 73.44%
Insider Trades by Quarter for Akorn (NASDAQ:AKRX)
Institutional Ownership by Quarter for Akorn (NASDAQ:AKRX)

Akorn (NASDAQ AKRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2017Brian TambiDirectorSell15,100$33.35$503,585.00View SEC Filing  
8/4/2017Brian TambiDirectorSell5,165$33.37$172,356.05View SEC Filing  
8/3/2017Bruce KutinskyCOOSell40,000$33.46$1,338,400.00317,480View SEC Filing  
8/15/2016Kenneth AbramowitzDirectorSell2,691$30.44$81,914.0420,786View SEC Filing  
6/14/2016Joseph BonaccorsiSVPSell6,500$29.84$193,960.00449,112View SEC Filing  
6/10/2016Kenneth AbramowitzDirectorSell14,675$30.16$442,598.0033,185View SEC Filing  
6/9/2016Bruce KutinskyCOOSell142,000$31.12$4,419,040.0058,695View SEC Filing  
6/7/2016Ronald M JohnsonDirectorSell7,542$31.49$237,497.58111,807View SEC Filing  
6/6/2016Kenneth AbramowitzDirectorSell10,900$31.37$341,933.0016,985View SEC Filing  
6/3/2016Joseph BonaccorsiSVPSell90,250$31.23$2,818,507.50470,862View SEC Filing  
6/2/2016Alan D WeinsteinDirectorSell50,000$30.93$1,546,500.0083,857View SEC Filing  
4/21/2015Mark M SilverbergVPSell29,000$55.00$1,595,000.00View SEC Filing  
3/10/2015John N KapoorDirectorBuy19,000$44.26$840,940.00View SEC Filing  
3/3/2015Rajat RaiCEOBuy5,000$47.70$238,500.00View SEC Filing  
2/18/2015Joseph BonaccorsiInsiderSell40,827$47.33$1,932,341.91View SEC Filing  
2/10/2015Ronald M JohnsonDirectorSell17,173$46.44$797,514.12View SEC Filing  
1/26/2015Rajat RaiCEOSell873,985$41.89$36,611,231.65View SEC Filing  
1/12/2015Mark M SilverbergVPSell38,602$41.00$1,582,682.00View SEC Filing  
1/9/2015Ronald M JohnsonDirectorSell17,173$40.46$694,819.58View SEC Filing  
1/2/2015Ronald M JohnsonDirectorSell14,300$36.12$516,516.00View SEC Filing  
1/2/2015Timothy A DickCFOSell30,150$36.03$1,086,304.50View SEC Filing  
12/15/2014Brian TambiDirectorSell1,200$41.86$50,232.00View SEC Filing  
12/12/2014Adrienne L GravesDirectorSell9,557$41.09$392,697.13View SEC Filing  
12/11/2014John N KapoorDirectorSell50,000$41.19$2,059,500.00View SEC Filing  
12/9/2014John R SabatVPSell43,173$40.53$1,749,801.69View SEC Filing  
12/1/2014Timothy A DickCFOSell30,875$39.23$1,211,226.25View SEC Filing  
11/3/2014Timothy A DickCFOSell122,222$44.08$5,387,545.76View SEC Filing  
10/1/2014Timothy A DickCFOSell122,222$35.24$4,307,103.28View SEC Filing  
9/12/2014Brian TambiDirectorSell13,800$38.00$524,400.00View SEC Filing  
9/11/2014Joseph BonaccorsiInsiderSell116,800$37.89$4,425,552.00View SEC Filing  
9/8/2014Kenneth AbramowitzDirectorSell4,500$36.54$164,430.00View SEC Filing  
9/8/2014Rajat RaiCEOSell147,000$36.78$5,406,660.00View SEC Filing  
9/8/2014Timothy A DickCFOSell45,000$37.61$1,692,450.00View SEC Filing  
9/4/2014Alan D WeinsteinDirectorSell5,000$38.49$192,450.00View SEC Filing  
8/26/2014John N KapoorDirectorSell50,000$38.99$1,949,500.00View SEC Filing  
8/7/2014Rajat RaiCEOSell903,659$33.62$30,381,015.58View SEC Filing  
6/13/2014Brian TambiDirectorBuy1,000$27.62$27,620.00View SEC Filing  
5/16/2014Rajat RaiCEOBuy5,000$26.76$133,800.0031,271View SEC Filing  
5/14/2014Kenneth AbramowitzDirectorSell2,557$26.79$68,502.034,300View SEC Filing  
12/9/2013Alan WeinsteinDirectorSell20,000$25.52$510,400.0053,857View SEC Filing  
12/3/2013Kenneth AbramowitzDirectorSell5,000$25.35$126,750.0021,057View SEC Filing  
12/12/2012Alan D WeinsteinDirectorBuy30,500$13.67$416,935.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Akorn (NASDAQ AKRX) News Headlines

Source:
DateHeadline
BidaskClub Lowers Akorn (AKRX) to Strong SellBidaskClub Lowers Akorn (AKRX) to Strong Sell
www.americanbankingnews.com - January 20 at 12:33 PM
Notable Tuesday Option Activity: AKRX, ROK, CBRLNotable Tuesday Option Activity: AKRX, ROK, CBRL
www.nasdaq.com - January 10 at 9:01 AM
Akorn, Inc. (AKRX) Receives Average Rating of "Hold" from AnalystsAkorn, Inc. (AKRX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 9 at 1:40 AM
Fresenius CFO backs acquisition course: Boersen-ZeitungFresenius CFO backs acquisition course: Boersen-Zeitung
www.reuters.com - January 7 at 9:24 AM
Pomerantz LLP and Glancy Prongay & Murray LLP announce that the United States District Court for the Northern District of Illinois, Eastern Division, has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Akorn, Inc.Pomerantz LLP and Glancy Prongay & Murray LLP announce that the United States District Court for the Northern District of Illinois, Eastern Division, has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Akorn, Inc.
finance.yahoo.com - January 4 at 8:39 AM
Akorn Reaches Analyst Target Price - NasdaqAkorn Reaches Analyst Target Price - Nasdaq
www.nasdaq.com - January 1 at 3:26 PM
Pomerantz LLP and Glancy Prongay & Murray LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Akorn, Inc. - AKRXPomerantz LLP and Glancy Prongay & Murray LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Akorn, Inc. - AKRX
finance.yahoo.com - December 29 at 9:17 AM
Akorn (AKRX) Shares Cross Below 200 DMAAkorn (AKRX) Shares Cross Below 200 DMA
www.nasdaq.com - December 22 at 8:27 AM
Fresenius now sees completion of Akorn takeover in early 2018Fresenius now sees completion of Akorn takeover in early 2018
finance.yahoo.com - December 19 at 8:59 AM
BidaskClub Downgrades Akorn (AKRX) to Strong SellBidaskClub Downgrades Akorn (AKRX) to Strong Sell
www.americanbankingnews.com - December 17 at 7:44 AM
Akorn, Inc. (AKRX) Receives Consensus Rating of "Hold" from BrokeragesAkorn, Inc. (AKRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 15 at 1:50 AM
ETFs with exposure to Akorn, Inc. : December 13, 2017ETFs with exposure to Akorn, Inc. : December 13, 2017
finance.yahoo.com - December 13 at 3:26 PM
ETFs with exposure to Akorn, Inc. : December 1, 2017ETFs with exposure to Akorn, Inc. : December 1, 2017
finance.yahoo.com - December 1 at 11:18 AM
Akorn, Inc. (AKRX) Director Brian Tambi Sells 15,100 SharesAkorn, Inc. (AKRX) Director Brian Tambi Sells 15,100 Shares
www.americanbankingnews.com - November 22 at 7:57 PM
Akorn, Inc. breached its 50 day moving average in a Bearish Manner : AKRX-US : November 22, 2017Akorn, Inc. breached its 50 day moving average in a Bearish Manner : AKRX-US : November 22, 2017
finance.yahoo.com - November 22 at 4:18 PM
Analyzing Akorn (AKRX) and Its CompetitorsAnalyzing Akorn (AKRX) and Its Competitors
www.americanbankingnews.com - November 21 at 7:34 PM
Merck & (MRK) vs. Akorn (AKRX) Financial SurveyMerck & (MRK) vs. Akorn (AKRX) Financial Survey
www.americanbankingnews.com - November 19 at 9:26 PM
ETFs with exposure to Akorn, Inc. : November 17, 2017ETFs with exposure to Akorn, Inc. : November 17, 2017
finance.yahoo.com - November 17 at 2:57 PM
Analyzing Akorn (AKRX) & Its RivalsAnalyzing Akorn (AKRX) & Its Rivals
www.americanbankingnews.com - November 13 at 3:34 AM
Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Akorn ...Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Akorn ...
www.prnewswire.com - November 11 at 8:55 AM
Short Interest in Akorn, Inc. (AKRX) Increases By 14.2%Short Interest in Akorn, Inc. (AKRX) Increases By 14.2%
www.americanbankingnews.com - November 11 at 3:40 AM
Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Akorn, Pacira Pharma, and Rigel PharmaBreakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Akorn, Pacira Pharma, and Rigel Pharma
www.bizjournals.com - November 10 at 7:32 PM
ETFs with exposure to Akorn, Inc. : November 6, 2017ETFs with exposure to Akorn, Inc. : November 6, 2017
finance.yahoo.com - November 6 at 4:28 PM
Financial Review: Akorn (AKRX) and Its PeersFinancial Review: Akorn (AKRX) and Its Peers
www.americanbankingnews.com - November 5 at 1:10 AM
Traders Buy High Volume of Akorn Call Options (AKRX)Traders Buy High Volume of Akorn Call Options (AKRX)
www.americanbankingnews.com - November 4 at 1:58 AM
Akorn, Inc. :AKRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Akorn, Inc. :AKRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 3:39 PM
Reviewing Akorn (AKRX) and The CompetitionReviewing Akorn (AKRX) and The Competition
www.americanbankingnews.com - November 3 at 3:18 AM
Akorn/Fresenius: Risky Arb - Seeking AlphaAkorn/Fresenius: Risky Arb - Seeking Alpha
seekingalpha.com - November 2 at 4:04 PM
Fresenius says Akorn troubles could continue into next yearFresenius says Akorn troubles could continue into next year
finance.yahoo.com - November 2 at 4:04 PM
Akorn (AKRX) Chairman John Kapoor Resigns; Alan Weinstein to Assume Role - StreetInsider.comAkorn (AKRX) Chairman John Kapoor Resigns; Alan Weinstein to Assume Role - StreetInsider.com
www.streetinsider.com - November 1 at 3:08 AM
The U.S. Has A Fentanyl Shortage...In The Clinic, Not On The StreetsThe U.S. Has A Fentanyl Shortage...In The Clinic, Not On The Streets
finance.yahoo.com - October 31 at 10:06 PM
Insys founder Kapoor steps down as Akorn chairman after arrestInsys founder Kapoor steps down as Akorn chairman after arrest
finance.yahoo.com - October 31 at 5:03 PM
Comparing Akorn (AKRX) and Johnson & Johnson (JNJ)Comparing Akorn (AKRX) and Johnson & Johnson (JNJ)
www.americanbankingnews.com - October 28 at 9:12 PM
Akorn, Inc. breached its 50 day moving average in a Bearish Manner : AKRX-US : October 27, 2017Akorn, Inc. breached its 50 day moving average in a Bearish Manner : AKRX-US : October 27, 2017
finance.yahoo.com - October 27 at 5:53 PM
John Kapoor, Founder Of Insys, Indicted On Charges Of Bribing Doctors To Overprescribe OpioidsJohn Kapoor, Founder Of Insys, Indicted On Charges Of Bribing Doctors To Overprescribe Opioids
www.msn.com - October 26 at 3:44 PM
Pre-Market Most Active for Oct 26, 2017 : NOK, MTU, TWTR, NMR, VIPS, RING, CELG, ABY, NVS, LSXMK, AKRX, QQQ - NasdaqPre-Market Most Active for Oct 26, 2017 : NOK, MTU, TWTR, NMR, VIPS, RING, CELG, ABY, NVS, LSXMK, AKRX, QQQ - Nasdaq
www.nasdaq.com - October 26 at 11:08 AM
Akorn, Inc. (AKRX) Given Average Rating of "Hold" by AnalystsAkorn, Inc. (AKRX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - October 26 at 1:34 AM
Short Interest in Akorn, Inc. (AKRX) Rises By 19.9%Short Interest in Akorn, Inc. (AKRX) Rises By 19.9%
www.americanbankingnews.com - October 26 at 1:20 AM
ETFs with exposure to Akorn, Inc. : October 25, 2017ETFs with exposure to Akorn, Inc. : October 25, 2017
finance.yahoo.com - October 25 at 4:35 PM
Akorn, Inc. (AKRX) Raised to "Hold" at Zacks Investment ResearchAkorn, Inc. (AKRX) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 24 at 8:38 PM
Akorn, Inc. (AKRX) Receives Hold Rating from Piper Jaffray CompaniesAkorn, Inc. (AKRX) Receives Hold Rating from Piper Jaffray Companies
www.americanbankingnews.com - October 22 at 6:58 AM
Akorn, Inc. – Value Analysis (NASDAQ:AKRX) : October 16, 2017Akorn, Inc. – Value Analysis (NASDAQ:AKRX) : October 16, 2017
finance.yahoo.com - October 16 at 4:34 PM
Akorn, Inc. breached its 50 day moving average in a Bullish Manner : AKRX-US : October 13, 2017Akorn, Inc. breached its 50 day moving average in a Bullish Manner : AKRX-US : October 13, 2017
finance.yahoo.com - October 13 at 3:38 PM
$236.10 Million in Sales Expected for Akorn, Inc. (AKRX) This Quarter$236.10 Million in Sales Expected for Akorn, Inc. (AKRX) This Quarter
www.americanbankingnews.com - October 7 at 1:50 PM
$0.24 Earnings Per Share Expected for Akorn, Inc. (AKRX) This Quarter$0.24 Earnings Per Share Expected for Akorn, Inc. (AKRX) This Quarter
www.americanbankingnews.com - October 5 at 4:28 AM
ETFs with exposure to Akorn, Inc. : September 29, 2017ETFs with exposure to Akorn, Inc. : September 29, 2017
finance.yahoo.com - October 2 at 3:34 PM
Mylan: Time To Sell?Mylan: Time To Sell?
seekingalpha.com - September 19 at 3:43 PM
Akorn, Inc. (AKRX) Sees Significant Increase in Short InterestAkorn, Inc. (AKRX) Sees Significant Increase in Short Interest
www.americanbankingnews.com - September 14 at 1:54 AM
Akorn, Inc. (Nasdaq: AKRX) to Ring The Nasdaq Stock Market Opening Bell - GlobeNewswire (press release)Akorn, Inc. (Nasdaq: AKRX) to Ring The Nasdaq Stock Market Opening Bell - GlobeNewswire (press release)
globenewswire.com - September 7 at 8:44 PM
Akorn, Inc. (Nasdaq: AKRX) to Ring The Nasdaq Stock Market Opening BellAkorn, Inc. (Nasdaq: AKRX) to Ring The Nasdaq Stock Market Opening Bell
finance.yahoo.com - September 7 at 8:44 PM

SEC Filings

Akorn (NASDAQ:AKRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Akorn (NASDAQ:AKRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Akorn (NASDAQ AKRX) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.